Program
pimicotinib
Also written as “pimicotinib capsules”, “ABSK021” and “Pimicotinib”.
Its studies are mostly in Giant Cell Tumor of Tendon Sheath · Synovitis, Pigmented Villonodular · Neoplasms · Pancreatic Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbisko Cayman | 135 open or running | phase 3since Mar 13, 2023 | Nov 27, 2019 | Dec 31, 2031phase 1 · NCT04192344 |
| Merck KGaA, Darmstadt, Germany | 11 open or running | phase 2since Mar 23, 2026 | Mar 23, 2026 | Aug 22, 2028phase 2 · NCT07499362 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Nov 27, 2019.
- Mar 7, 2022Phase 1 study in NeoplasmsAbbisko Cayman · NCT05280483 · 16 enrolled · China
- Mar 13, 2023Phase 3 study in Giant Cell Tumor of Tendon SheathAbbisko Cayman · NCT05804045 · 94 enrolled · United States, Canada, China and more
- Oct 20, 2023Phase 2 study in Advanced Pancreatic CancerAbbisko Cayman · NCT06111274 · 82 planned · China
- Nov 20, 2023Phase 1 study in Healthy SubjectsAbbisko Cayman · NCT06186583 · 6 enrolled · China
- Nov 28, 2023Phase 2 study in cGvHDAbbisko Cayman · NCT06186804 · 64 planned · China
- Feb 29, 2024Phase 1 study in Healthy SubjectsAbbisko Cayman · NCT06322706 · 36 enrolled · China
- Aug 18, 2024Phase 1 study in PharmacokineticsAbbisko Cayman · NCT06562946 · 24 enrolled · China
- Nov 14, 2024Phase 1 study in PharmacokineticsAbbisko Cayman · NCT06694948 · 26 enrolled · China
- Jan 9, 2025Phase 1 study in Healthy SubjectsAbbisko Cayman · NCT06779253 · 39 enrolled · China
- Mar 13, 2025Phase 1 study in Healthy SubjectsAbbisko Cayman · NCT06884072 · 16 enrolled · China
- Aug 3, 2025Phase 1 study in PharmacokineticsAbbisko Cayman · NCT07126249 · 38 enrolled · China
- Sep 30, 2025Phase 1 study in Pharmacokinetics in Healthy VolunteersAbbisko Cayman · NCT07210996 · 20 enrolled · China
- Mar 23, 2026Merck KGaA, Darmstadt, Germany's first study: phase 2 study in Giant Cell Tumor of Tendon SheathNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT07499362 · 20 planned · Japan
- Nov 9, 2026Primary completion moved from 2026-12-31 to 2031-12-31Date moved laterphase 1 · +60 months · NCT04192344
Ahead
- Aug 22, 2028Primary completion: phase 2 study in Giant Cell Tumor of Tendon SheathMerck KGaA, Darmstadt, Germany · NCT07499362
- Dec 31, 2031Primary completion: phase 1 study in NeoplasmsAbbisko Cayman · NCT04192344
TargetBeta
“An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), ”NCIt, by rule
Other programs on CSF1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| axatilimabrule | Incyte | phase 3 | 12 |
| vimseltinibrule | Ono Pharmaceutical | phase 3 | 8 |
| seralutinibrule | gb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-inc | phase 3 | 8 |
| adrixetinibrule | qurient-co-ltd | phase 2 | 3 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07499362Giant Cell Tumor of Tendon Sheath · Japan | 2 | Recruiting | Merck KGaA, Darmstadt, Germany | Aug 22, 2028 | 20 |
| NCT07210996Pharmacokinetics in Healthy Volunteers · China | 1 | Completed | Abbisko Cayman | Oct 6, 2025 | 20 |
| NCT07126249Pharmacokinetics · China | 1 | Completed | Abbisko Cayman | Jun 6, 2025 | 38 |
| NCT06884072Healthy Subjects · China | 1 | Active, not recruiting | Abbisko Cayman | Jul 1, 2025 | 16 |
| NCT06779253Healthy Subjects · China | 1 | Completed | Abbisko Cayman | Apr 4, 2025 | 39 |
| NCT06694948Pharmacokinetics · China | 1 | Completed | Abbisko Cayman | Jan 3, 2025 | 26 |
| NCT06562946Pharmacokinetics · China | 1 | Completed | Abbisko Cayman | Dec 30, 2024 | 24 |
| NCT06322706Healthy Subjects · China | 1 | Completed | Abbisko Cayman | Nov 1, 2024 | 36 |
| NCT06186804cGvHD · China | 2 | By invitation | Abbisko Cayman | Oct 30, 2026 | 64 |
| NCT06186583Healthy Subjects · China | 1 | Completed | Abbisko Cayman | May 30, 2024 | 6 |
| NCT06111274Advanced Pancreatic Cancer · China | 2 | Recruiting | Abbisko Cayman | Dec 30, 2025 | 82 |
| NCT05804045Giant Cell Tumor of Tendon Sheath · United States, Canada, China and more | 3 | Active, not recruiting | Abbisko Cayman | Sep 23, 2024 | 94 |
| NCT05280483Neoplasms · China | 1 | Completed | Abbisko Cayman | Aug 31, 2022 | 16 |
| NCT04192344Neoplasms · United States, China | 1 | Recruiting | Abbisko Cayman | Dec 31, 2031 | 276 |
How it is read
Names in the registry
- “pimicotinib capsules”, 4 entries
- “ABSK021”, 3 entries
- “Pimicotinib”, 2 entries
- “Pimicotinib(ABSK021)”, 1 entry
- “Pimicotinib capsule”, 1 entry
Codes read as this program: ABSK021.
Conditions, from the studies’ own filings
- Giant Cell Tumor of Tendon Sheath, 2 studies
- Synovitis, Pigmented Villonodular, 1 study
- Neoplasms, 1 study
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.